Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GP2 peptide + GM-CSF + trastuzumab
- Development stage
- Unknown
- Lead developer
- Greenwich LifeSciences
- Modality
- Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
GP2 peptide + GM-CSF + trastuzumab is a three-component combination regimen used in the adjuvant treatment of HER2-positive breast cancer. The GP2 peptide is a HER2-derived immunogenic peptide (epitope HER2:654-662) designed to stimulate a CD8+ T cell-mediated immune response to HER2-positive tumor cells. GM-CSF (granulocyte-macrophage colony-stimulating factor) is an immunoadjuvant that enhances the vaccine's cellular immune response. Trastuzumab is a recombinant humanized IgG1 monoclonal antibody that targets the extracellular domain of the HER2 receptor, directly inhibiting HER2 signaling and inducing antibody-dependent cell-mediated cytotoxicity. Clinical trials have demonstrated that this combination is safe and may provide a synergistic benefit in improving disease-free survival rates in HER2-positive breast cancer, particularly when GP2+GM-CSF is administered concurrently or sequentially with trastuzumab[1][3][5].
- Brand names
- HerceptinHerzumaOntruzant
- Other names
- granulocyte-macrophage colony-stimulating factor vaccineGM-CSF vaccine
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)HLA-A*03:01 (DARKFOX-A3 peptide-HLA-A*03:01 complex)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on GP2 peptide + GM-CSF + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GP2 peptide + GM-CSF + trastuzumab.